Nanoparticle Based Targeting Approaches for Lung Cancer: A Mini Review

Brijeshkunvar Mishra[1*], Jagdish Chandra Pati [2], Richa Mishra[3] and Manmeet Singh Saluja[2]

[1]Research Scholar, Sunrise University, Alwar, Rajasthan, India
[2]Research Supervisor, Sunrise University, Alwar, Rajasthan, India
[3]Director, RB Science (Research Lab), Bhopal, Madhya Pradesh, India
*Corresponding Author

Abstract— Every year more than 10 million people are diagnosed with cancer and more than 6 million deaths – around 12% of deaths worldwide. The objective of cancer treatment still is to cure the patients if possible or prolong their life and improve their quality of life by surgical removal of the cancerous tissue, radiation therapy, biotherapy, chemotherapy, bone marrow transplant or a combination of some of these available treatments. This review aims to explore the various approaches using nanotechnology and surface decoration with ligands capable to target lung cancers.

Keywords— Cancer, targeting, nanoparticles, lungs, chemotherapy.

I.   INTRODUCTION

1.1   Cancer chemotherapy and controlled drug delivery

Cancer is any malignant growth caused by abnormal or uncontrolled cell division eventually spreading to other parts of the body through the lymphatic or the circulatory system [90]. Every year more than 10 million people are diagnosed with cancer and more than 6 million deaths – around 12% of deaths worldwide [1]. It has been estimated that there will be 17 million new cases of cancer every year by 2027.

The objective of cancer treatment still is to cure the patients if possible or prolong their life and improve their quality of life by surgical removal of the cancerous tissue, radiation therapy, biotherapy, chemotherapy, bone marrow transplant or a combination of some of these available treatments [2]. It is estimated that more than 50% of the patients of cancer receive systemic chemotherapy as a part of their treatment regimen [3].

Chemotherapy is the use of chemical for treatment or it can be defined as "curing by chemicals" [4]. During chemotherapy, cycles of drugs are prescribed, at interval of three to four weeks, over a treatment period of four to six months. During these cycles, the normal cells (blue line) recover whereas the tumor cells (red line) do not (Fig. 1). Though highly effective in curing the disease, chemotherapy by the use of anticancer drugs possess a lot of adverse effects and has a number of disadvantages.


Fig.1 Chemotherapy cycles [4]

The main disadvantage of chemotherapy is that normal cells, especially those that divide quickly like bone marrow, lining of gastrointestinal tract or the hair follicles, are also harmed by the anticancer drugs [5].

An effective and advantageous alternative to the conventional chemotherapy is the use of controlled drug delivery systems thereby attaining the release of drug in a predesigned manner from the carrier material [6].

A controlled drug delivery system can improve the efficacy of the drug by rendering sustained and effective drug release (Fig. 2) and also reduce the toxicity and side effects of the anticancer drug [7]. It provides a sustained and effective drug level and improved patient compliance and convenience.


Fig.2 Drug levels in blood with conventional dosing (left) and controlled drug delivery (right) [97]

1.2 Lung cancer

Lung cancer is a condition in which the tissues in lungs grow out of control. A majority of cancers of lungs are carcinomas arising from the epithelial tissues. It is responsible for death of around 1.3 million people worldwide. The most common symptoms of lung cancer are shortness of breath, coughing and weight loss [8].

There are two main types of lung cancers that can be characterized by the size and appearance of the malignant cells as visible under a microscope: non-small cell and small cell lung carcinoma.

About 85% to 90% of the lung cancers are non-small cell lung cancers (NSCLC) categorized in three main subtypes: squamous cell carcinoma, adenocarcinoma and large cell carcinoma [9].

Once the cancer is diagnosed and staged, any one or combination of surgery, radiation therapy, chemotherapy or targeted therapies may be used for treatment.

The chemotherapeutic agents most frequently used in NSCLC are cisplatin, paclitaxel, carboplatin, docetaxel, vinorelbine and vinblastin. In cases of advanced lung cancers, targeted therapy drugs such as bevacizumab, and cetuximab can be included in the treatment paradigm. The targeted therapies used in the treatment of NSCLC are designed to inhibit tumor angioneogenesis; inbihit the epidermal growth factor receptor (EGRF) or the ALK gene [10].

1.3 Targeted drug delivery systems for lung cancers

The past two decades have been witnessing a lot of research being directed towards targeting of drug molecules to the desired site of action using novel drug delivery systems like nanoparticles. A Pubmed search using "nanoparticles for drug delivery" as the key entry revealed 15266 entries from 2003 to 2023 whereas only 15964 entries from 1990 to 2013. Nanoparticles can be administered via different routes such as oral, parenteral or by pulmonary inhalation. Aerosol therapy [11] with the use of particulate drug carriers is gaining popularity these days as evident from the development of inhalable insulin [12].

The lungs constitute the largest external surface area in the human body, which facilitates an efficient exchange of gases between the blood stream and air. The large alveolar surface area, the low thickness of the epithelial barrier, extensive vascularization and a comparatively lower proteolytic activity in the aleveoli and the absence of a first-pass metabolism phenomenon [13] helps in increasing drug absorption and the particulate carrier delivery to the lungs. Nanoparticle delivery to lungs can lead to retention of the particles in the lungs thereby causing a prolonged drug release [14] and studies have shown that particle uptake by alveolar macrophages can be reduced if the particle size is smaller than 260 nm [15].

Several drug delivery systems capable of selectively localizing the drug in the lungs have been developed. The use of external ligands like antibodies, aptamers, proteins, peptides and other small molecule as ligands attached to the nanoparticle carriers results in targeted delivery [16].

The molecular targets that can be used for targeted therapy to the lungs and the various ligand

Int. J. Med. Phar. Drug Re., 7(4), 2023

Online Available at: https://www.aipublications.com/ijmpd/

63

conjugated delivery systems that have been developed for targeted delivery have been reviewed in this chapter. In addition to lung targeting, a few other novel delivery systems based on nanocarriers have been reviewed.

1.4   Nanoparticle targeting to lungs after intravenous injection

Initial studies performed by different researchers to investigate the biodistribution of nanoparticles after iv injection showed that the main sites of accumulation of the nanoparticles were the organs of the reticuloendothelial system such as liver, spleen and the lungs [17].

A study by Kreuter et al [18] using poly (methyl-2-^{14}C-methacrylate) nanoparticles injected intravenously in mice and rats and measuring the radioactivity in different organs at different time intervals revealed that the maximum accumulation of the nanoparticles in lungs (21.8% of the administered dose) was after 30 min, which eventually decreased to 13.2% after 7 days of administration of the nanoparticles. Similar distribution studies using different nanoparticles also confirmed that the nanoparticles were taken by the phagocytes of the RES and mainly distributed to the liver and in small portions to the lungs, spleen and the bone marrow [19]. Their study led to a generalization that for the passive targeting of nanoparticles to lungs, the particle size should be more than 7 μm so that the particles are retained in the alveolar capillaries. This occurs due to the breakdown of the repulsive forces of the nanoparticles after injection and their spontaneous agglomeration to form larger particles.

The microspheric particles with sizes ranging from 7-15 μm have been studied by Huo et al [20], Tao et al [211], Ozkan et al [22] and Eldem et al [23]. The findings of their studies indicate that the particles of 7-15 μm size range were able to get retained by the alveolar capillary barrier for longer period of time and thereafter taken up by the alveolar macrophages. The results of study by Eldem et al also cautioned that the particles with diameter of greater than 5 μm may lead to the blockade of blood capillaries and may cause chronic obstructive pulmonary emphysema. Zhang et al [24] reported a HDL-mimicking peptide-phospholipid scaffold (HPPS) nanocarrier for the delivery of diagnostic and therapeutic agents. In their study apoA-I protein of the plasma derived HDL was replaced with self-assembled apoA-I mimetic peptides on the nanoparticle surface. The resulting nanoparticles had a well-controlled size of less than 30 nm and they retained the HDL-like properties to carry the lipophilic payloads. HPPS was also found to mimic the pharmacokinetic properties and targeting specificity of apoA-I protein against scavenger receptor type B1 thereby permitting excellent delivery of the nanoparticles to the target cells.

A study performed by Gipps et al [25] using ^{14}C-polyhexyl cyanoacrylate nanoparticles injected intravenously in nude mice, inoculated with human osteocarcinoma showed that the maximum of 2.27% of the administered dose was accumulated in lungs after 1 h of administration. During a 14 day observation period, this level decreased to 1.11%; the highest levels of nanoparticle accumulation were found in the organs of the RES in their study. Kellaway and Farr [26] tested the possibility of liposomes as drug delivery systems for lung-targeting. Their findings suggested that large particles and liposomes with positive surface charge could be trapped in the capillary beds of the lungs. Waser et al [27] used liposomes, ^{14}C-hexylcyanoacrylate nanoparticles and ^{125}I-albumin nanoparticles to demonstrate that after intravenous injection, the particles could be accumulated in lungs in relatively high concentrations.

Leucata et al [28] compared the pharmacokinetic profile of epirubicin loaded nanoparticles, liposomes and free epirubicin following an intravenous administration of the preparations. A higher level of nanoparticles and liposomes could be found in the lungs but the half life was not significantly increased and the accumulation in lungs was reported to be unimproved in relation to the free drug. In a study initiated by Zara et al [29] on solid lipid nanoparticles loaded with doxorubicin, the concentration of nanoparticles in lungs followed by intravenous injection was found to be much higher compared to the doxorubicin solution. Following an intravenous injection of ^{14}C-azidothymidine attached to hexylcyanoacrylate nanoparticle drugs, Lobenberg et al [30] found that the concentration of Azidothymidine bound to nanoparticles in the lungs compared to control solution was 18 times higher

Int. J. Med. Phar. Drug Re., 7(4), 2023

Online Available at: https://www.aipublications.com/ijmpd/

64

after 8 h of administration. While studying the biodistribution of methotrexate-loaded bovine serum albumin nanoparticles, Santhi et al reported 33.14% drug increase in lungs using the nanoparticles compared to the free drug [31]. Solid lipid nanoparticles loaded with dexamethasone acetate developed by Huang et al [32] using high pressure homogenization method and administered intravenously revealed a 17.8 fold increase in the concentration of SLNs in the lungs as compared to dexamethasone solution after 30 minutes of administration.

Table 1 Some attempts for intravenous administration of nanoparticles for lung targeting

Nanoparticle	Lung accumulation	Reference
Poly (methyl-2-^{14}C-methylacrylate)	21.8%, 30 min after injection and 13.2% after 7 days of injection	[18]
^{14}C-polyhyxyl cyanoacrylate	2.27%, 1 h after administration	[15]
Hexylcyanoacrylate and albumin nanoparticles	Higher accumulation relative to the control solution	[17]
^{14}C-polylactic acid (PLA) nanoparticles	Negligible after day 1 and 7	[33]
^{14}C-amino-modified polystyrene	Less than 1% at 2 min after injection	[34]
Polyhexylcyanoacrylate	Negligible after 6, 18 and 24 h of administration	[35]
Poly (methyl methacrylate)	No improved accumulation compared to control solution	[36]
Polybutylcyanoacrylate	Lower drug concentration relative to free drug solution	[37]
Gelatin	No significant change in accumulation as compared to free drug solution	[38]
Solid lipid nanoparticles	Higher concentration compared to control solution	[29]
Bovine serum albumin	33.14% increase compared to free drug	[311]
Hexylcyanoacrylate	18 times drug concentration increase in lungs compared to control solution	[30]
Surfactant-coated polymethyl [2-14C] Methacrylate	7%, 24 h after administration	[38]
Albumin	Significant tumor response	[39]

1.5 Ligands for targeting lungs

The use of ligands attached along with the carrier can be helpful in bioadhesion, cell uptake or transcytosis of the delivery system thereby increasing the targeting efficiency of the delivery system. The development of molecular biology, proteomics and combinatorial approaches has led to the screening of more and more targeting ligands. Some of the ligands proven to be effective in targeting of the particulate delivery systems to lungs are given in Table 2.

Table 2 Some ligands capable of targeting delivery system to lungs [40]

Ligand	Receptor	Effect	Reference
Lectin	Lectin receptor	Improved uptake of drugs and liposomes into airway cell	[41]

Int. J. Med. Phar. Drug Re., 7(4), 2023

Online Available at: https://www.aipublications.com/ijmpd/   65

		cultures	
Sugars	Lectin receptors	More efficient uptake by airway epithelial cells in culture	[42, 43]
	Alveolar macrophage receptors	Specific, enhanced endocytic uptake into alveolar macrophages	[44, 45]
Immuno-globulins	IgG		[46, 47]
Lipo-proteins	SP-A	Increased drug and liposome delivery to airway cells	[48-50]
EGF	rEGF	Efficient DNA uptake into cancer cells	[51-53]
Mono-clonal Abs	ICO-25 Mab	Specific delivery to tumor cells of epithelial origin	[54]
	Anti-ICAM-1 antibodies	IFN-gamma activated human bronchial epithelial cells (BEAS-2B)	[55]
Peptides	THALWHT	Specific binding and uptake into human airway epithelial cells in vitro	[56]
	linear/cyclic PLAEIDGIEL	Efficient DNA delivery to airway cells in culture	[57]
	RGD	Increased gene transfer Efficiency	[58]
Receptor agonists/ antagonists	UTP	Efficient gene transfer in human airway cells	[59]
	Folate	Efficient internalization into FR-expressing murine lung carcinoma cell line	[60]
	Transferrin	Improved uptake into alveolar epithelial cells	[61]

IGg, immunoglobulin; rEGF, recombinant epidermal growth factor; SP-A, surfactant protein A; RGD (peptide sequence); PLAEIGIEL (peptide sequence); Uridine 5'Triphosphate (UTP).

1.6   Lung Vascular Receptors

More than 40 different cell types are known to be present as components of the human lung vascular bed and respiratory airways [62]. Techniques like phage display, cDNA array and cell culture methods have been helpful in identifying some potential receptors in the lung vasculature that may be targeted for an effective drug delivery (Table 3).

Table 3 Some preferentially expressed receptors in lung vasculature [63]

Lung vasculature receptor	Localization
Identified using cell culture methods	
α-galactose and α-N-actyl-galactosamine	Microvascular endothelial cells
α- and β-N-actyl-galactosamine	Pulmonary artery derived endothelial cells
E-cadherin	Microvascular endothelial cells (not expressed by artery endothelial cells)
Identified using Phage display	
Membrane dipeptidyl peptidase (CD26)	Lung endothelial cells
Identified using cDNA array	
Phospholipase A2 group XII	Lung endothelial cells
Secreted frizzled related protein 1 (sFRP1	Lung endothelial cells
Osteoglycin	Lung endothelial cell, smooth muscle cell, around cartilage and alveoli
Using other approaches	
Ca^{2+}-activated chloride channels (human CLCA-2/mouse CLCA-1/Lu-ECAM-1)	Endothelia of the aorta and pulmonary venules
Dipeptidyl peptidase IV (CD26)	Lung endothelium
Angiotensin converting enzyme (ACE) (lung selective marker)	Endothelial luminal surface
Platelet-endothelial adhesion molecule-1 (PECAM-1)/CD31 (lung selective marker)	Intercellular borders of the endothelial monolayer
Aminopeptidase P (APP)	Caveola of lung endothelium

1.7 Some nanoparticulate delivery systems used in cancer therapy

A few nanoparticulate delivery systems for anticancer molecules have also been reviewed for the purpose of designing novel polymeric system for drug targeting. Cheng *et al* [64] reported nanoparticle-aptamer bioconjugates for *in vivo* cancer therapy. Using prostate cancer as a model, they reported docetaxel encapsulated nanoparticles formulated with biocompatible and biodegradable PLGA-b-PEG copolymer surface functionalized with the A10 2′-fluoropyrimidine RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well characterized antigen expressed on the surface of prostate cancer cells.

Reddy and Murthy [65] developed etoposide loaded nanoparticles using melt- emulsification and homogenization followed by spray drying of nanodispersion. Functionalized polymeric nanoparticles have been synthesized by an emulsifier-free emulsion polymerization by Lepoittevin *et al* [66]. They used two monomers for polymerizatoin: 2-aminoethylmethacrylate and 4-(2-aminoethylthio) methylstyrene. Various glucose molecules such as maltose, galactopyranosyl ethanal lactose, and maltotriose were covalently grafted on to the surface of the nanoparticles by reductive amination or amidation.

Lee *et al* [67] formulated nanoparticles of poly (lactide)-tocopheryl polyethylene glycol succinate copolymer for protein drug delivery. Compared with

Int. J. Med. Phar. Drug Re., 7(4), 2023

Online Available at: https://www.aipublications.com/ijmpd/

67

other biodegradable polymeric nanoparticles such as poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles, the PLA-TPGS nanoparticles were able to provide the encapsulated proteins with a milder environment. Confocal laser scanning microscopy (CLSM) observation demonstrated the intracellular uptake of the PLA-TPGS NPs by NIH-3T3 fibroblast cells and Caco-2 cancer cells. A study by Gao *et al* [68] on novel DOCA modified CM-curdlan (DCMC) conjugate self-assembled nanoparticles loaded with epirubicin exhibited drug release in sustained manner. The *in vitro* anti-tumor studies using MCF-7 cells showed that the nanoparticles were more cytotoxic than the drug alone, which was due to the higher uptake of the nanoparticles in tumor. *In vivo* studies indicated that DCMC conjugate did not cause unexpected side effects. A study was conducted by Paranjape *et al* [69] to design tumor-targeted bioconjugate based delivery of camptothecin. A novel CPT bioconjugate was synthesized using carbodiimide chemistry with a linear PEG and amino acid glycine, respectively as the spacer and linker. Folic acid was used as the ligand for targeting taking into consideration the presence of mechanism for folate receptor mediated endocytosis. The results indicated significantly higher efficacy of the bioconjugate in comparison to CPT. In an investigation by Jain *et al* [70] on tumor targeted doxorubicin loaded surface tailored solid lipid nanoparticles (SLNs) conjugated with mannose, it was found that the biodistribution of drug from mannosylated SLNs was higher in the tumor mass as compared to the non-mannosylated SLNs. Chandna *et al* [71] compared the influence of different characteristics of nanocarriers on the efficacy of chemotherapy and imaging. It was evident from the results of their study that targeting to cancer cells by LHRH peptide enhanced antitumor activity of all tested nanocarriers. Park *et al* [72] prepared Adriamycin encapsulated nanoparticles using deoxycholic acid conjugated dextran and evaluated its antitumor activity using CT 26 tumor cells *in vitro* and *in vivo*. The nanoparticles were found to be promising vehicles for antitumor drug delivery. In another study Park *et al* [73] reported a delivery system comprising of modified heparin-DOCA conjugate as drug carrier for cancer therapy. The conjugate was able to prevent squamous cell

carcinoma and human umbilical vascular endothelial cell proliferation during bromodeoxyuridine (BrdU) incorporation assays.

Bozkir and Saka [74] reported the formulation of 5-FU nanoparticles using factorial design studies. They used the approach of an orthogonal experimental design to optimize the formulation of 5-fluorouracil (5-FU) loaded poly D,L (lactide-co-glycolide) (PLGA) nanoparticles (5FU-NP) by a nanoprecipitation-solvent displacement method. Maghsoudi *et al* [75] studied bovine serum albumin (BSA) nanoparticles loaded with 5-fluorouacil. The BSA nanoparticles suspension was found to maintain a constant release of drug for 20 h under experimental conditions and hence was found to be capable of releasing drug in a sustained manner over prolonged time period. Zhang *et al* [76], studied the anti-carcinoma effect of chitosan-polyaspartic acid-5-fluorouracil nanoparticle on tumor growth in nude mice. The tumor inhibition rates for the CTS-Pasp, 5-FU and CTS-Pasp-5FU groups were 5.09%, 65.3% and 72.79%, respectively. Yassin *et al* [77] performed a study using 5-FU solid lipid nanoparticles consisting of triglyceride esters, DynasanTM 114 or DynasanTM 118 along with soya lecithin as the lipid parts to treat colon cancer. The results exhibited a delayed release of the loaded drug in simulated colonic medium containing rat caecal contents.

Nanoparticles of particular sizes are known to have capacity to penetrate the BBB. The ability of such nanoparticles to cross the BBB has been utilized for targeted delivery of drugs to the CNS by Tosi *et al* [78]. They derivatized PLA with g7 peptide and the resulting g7 nanoparticles were loaded with loperamide and rhodamine-123 in order to assess their ability as drug carriers to the CNS. A study reported by Cho *et al* [79] showed the targeting capability of surface modified trans-retinoic acid (RA) loaded PLA nanoparticles. The study was carried out by using galactose as the hepatocyte-specific targeting ligand. It was found that the shapes of most hepatocytes attached onto polystyrene dish precoated with collagen solution were flat and spreading at low concentration of RA for the RA-loaded nanoparticles, whereas their shapes were round at even low concentration of RA when RA was mixed with the nanoparticles. De-Hong Yu *et al* [80] investigated K237-(HTMYYHHYQHHL) peptide-

Int. J. Med. Phar. Drug Re., 7(4), 2023

Online Available at: https://www.aipublications.com/ijmpd/

conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor vasculature. The K237 conjugated nanoparticles were found to be significantly internalized by human umbilical vein endothelial cells (HUVEC) through the K237-KDR interaction, and this facilitated uptake was considered to be responsible for the enhanced antiangiogenic activity shown by HUVEC proliferation, migration and tube formation compared to cells treated with the commercial formulation Taxol® and PTX-NP.

Dubey *et al* [81] in their study performed biological evaluation of paclitaxel loaded biodegradable PCL/PEG nanoparticles for the treatment of human neuroendocrine pancreatic tumor in mice. The PCL-Ptx nanoparticles reduced tumor volume significantly in comparison with paclitaxel. A biphasic release pattern was obtained for Paclitaxel-loaded PEGylated PLGA-based nanoparticles by Danhier *et al* [82]. The *in vitro* anti-tumoral activity was assessed using the Human Cervix Carcinoma cells (HeLa) by the MTT test relative to the commercial formulations Taxol® and Cremophor® EL. Ptx-loaded nanoparticles showed greater tumor growth inhibition effect *in vivo* on TLT tumor as compared to Taxol®. Kou *et al* [83] investigated paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single chain antibody. PTX-NP-S was shown to retain the specific antigen-binding affinity of SMFv-polylys to SM5-1 binding protein-positive Ch-hep-3 cells. The cytotoxicity of PTX-NP-S was also evaluated by a non-radioactive cell proliferation assay. It was evident from the results that PTX-NP-S had significantly enhanced *in vitro* cytotoxicity against Ch-hep-3 cells as compared with non-targeted paclitaxel-loaded PLGA nanoparticles.

II.   CONCLUSION

The objective of this review was to explore various nanotechnology based approached used to target drug delivery to lungs for treatment of lung cancers. It could be concluded from the review that the use of ligand as surface decorations has enabled a plethora of domains and portals to channelize the localization of drug in higher amounts to the desired organ or tissue.

REFERENCES

[1] WHO website, http://www.who.int/cancer/en.html. Last assessed 13 July 2016.

[2] Oncology: treatment and management. Part 2, Cancer treatment. Pharmaceutical representative, November 2002

[3] Feng SS, Chien S. Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003; 58: 4087-4114.

[4] Ehrlich P. Chemotherapeutics: Scientific principles, methods and results. Lancet 1913; 182(4694): 445-451.

[5] http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf; last assessed 13 July 2016.

[6] Lisa Brannon-Peppas. Polymers in controlled drug delivery. Medical Plastics and Biomaterials 1997; 4: 34-45.

[7] Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TGPS. J Control Release 2003; 86(1): 33-48.

[8] Silverberg E, Boring CC, Squires TS. Cancer statistics. CA Cancer J Clin 1990; 40(1): 9-26.

[9] http://en.wikipedia.org/wiki/Lung_cancer; last accessed 27 August 2015.

[10] Zhou F, Zhou Cai-Cun. Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. Chinese J Cancer 2015; 34: 31-41.

[11] Ely L, Roa W, Finlay WH, Lobenberg R. Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm 2007; 65(3): 346-353.

[12] Quattrin T. Inhaled insulin: recent advances in the therapy of Type 1 and 2 diabetes. Expert Opin Pharmacother 1992; 8: 2597-2604.

[13] Patton JS, Platz RM. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 1992; 8: 179-196.

[14] Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-1871.

[15] Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci 2002; 99: 12001-12005.

[16] Taylor G, Kellaway I. Pulmonary drug delivery. In: Hiller A, Lloyed A, Swarbricks J, eds. Drug Delivery and Targeting, New York: Taylor & Francis, 2001: 269-300.

[17] Lorenzer C, Dirin M, Winlker A-M, BaumannV, Winlker J. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 2015; 203: 1-10.

[18] Kreuter J, Tauber U, Illi V. Distribution and elimination of poly (metyl-2-14C-methacrylate) nanoparticle radiaoactivity after injection in rats and mice. J Pharm Sci 1979; 68(11): 1443-1447.

[19] Kreuter J. Evaluation of nanoparticles as drug-delivery systems III: materials, stability, toxicity, possibilities of targeting and use. Pharm Acta Helv 1983; 58(9-10): 242-250.

[20] Huo D, Deng S, Li L, Ji J. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. Int J Pharm 2005; 289: 63-67.

[21] Tao Y, Zhang HL, Hu YM, Wan S, Su ZQ. Preparation of chitosan and water soluble chitosan microspheres via spray drying method to lower blood lipids in rats fed with high-fat diet. Int J Mol Sci 2013; 14(2): 4174-4184.

[22] Ozkan Y, Diken M, Isimer A. Clarithromycin targeting to lung: optimization of size, morphology and release characteristics of albumin microspheres. Acta Pol Pharm – Drug Res 2000; 57(5): 375-380.

[23] Eldem T, Spieser P, Hincal A. Optimization of spray-dried and –congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm Res 1991; 8: 47-54.

[24] Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, Cao W, Lo PC, Yang M, Tsao MS, Luo Q, Zheng G., HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small Weinheim Bergstrasse Ger 2010; 6(3): 430–437

[25] Gipps EM, Arshady R, Kreuter J. Distribution of polyhexyl cyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. J Pharm Sci 1986; 75 (3): 256-258.

[26] Kellaway IW, Farr SJ. Liposomes as drug delivery systems to lung. Adv Drug Del Rev 1990; 5: 149-161.

[27] Waser PG, Muller U, Kreuter J, Berger S, Munz K, Kaiser E, Pfluger B. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice. Int J Pharm 1987; 39: 213-227.

[28] Leucauta SE, Achim M, Risca R, Pstescu ID. Preparation and pharmaceutical/pharmacokinetic characterization of liposomes and nanoparticles loaded with epirubicin. STP Pharm Sci 2013; 13(5): 291-297.

[29] Zara GP, Cavalli R, Fundaro A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicine incorporated in soid lipid nanoshpheres. Pharmacol Res 1999; 40(3): 281-286.

[30] Lobenberg R, Araujo L, Von Briesen H, RodgersE, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release 1998; 50(1-3): 21-30.

[31] Santhi K, Dhanaraj SA, Koshy M, Ponnusankar S, Suresh B. Study of biodistribution of methotrexate loaded bovine serum albumin nanospheres inmice. Drug Dev Ind Pharm 2000; 26(12): 1293-1296

[32] Xiang QY, Wang MT, Chen F, Gong T, Jian YL, Zhang ZR, Huang Y. Lung-targeted delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res 2007; 30(4): 519-525.

[33] Bazile DV, Ropert C, Huve P, Verrecchia T, Marlard M, Frydman A, Veillard M, Spenlehauer G. Body distribution of fully biodegradable [14C]-poly (lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992; 13(15): 1093-1102.

[34] Simon BH, Ando HY, Gupta PK. Circulation time and body distribution of 14C-labeled amino-modified polystyrene nanoparticles in mice. J Pharm Sci 1995; 84(10): 1249-1253.

[35] Page ME, Pinto-Alphandary H, Chachaty E, Andremont A, Couvreur P. Entrapment of colistin into polyhexylcyanoacrylate nanoparticles: preparation, drug release and tissue distribution in mice. STP Pharm Sci 1996; 6(4): 298-301.

[36] Chem J-H, Wang L, Ling R, Li Y, Wang Q, Yao Z, Ma Z. Body distribution of nanoparticle containing adriamycin injected into the hepatic artery of hepatoma-bearing rats. Dig Dis Sci 2004; 49(7-8): 1170-1173.

[37] Teng KY, Lu Z, Wientjes MG, Au JL-S. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005; 22(6): 867-874.

[38] Leu D, Manthey B, Kreuter J. Distribution and elimination of coated polymethyl [2-14C]methacrylate nanoparticles after intravenous injection in rats. J Pharm Sci 1984; 73(10): 1433-1437.

[39] Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Kawkins MJ. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17(8): 1263-1268.

[40] Cryan S-A. Carrier based strategies for targeting protein and peptide drugs to the lungs. The AAPS J 2005; 7(1): E20-E41.

[41] Yanagihara K, Cheng PW. Lectin enhancement of the lipofection efficiency in human lung carcinoma cells. Biochim Biophys Acta 1999; 1472:25-33.

Int. J. Med. Phar. Drug Re., 7(4), 2023

Online Available at: https://www.aipublications.com/ijmpd/

70

[42] Fajac I, Briand P, Monsigny M, Midoux P. Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells. Human Gene Ther 1999; 10: 395-406.

[43] Fajac I, Thevenot G, Bedouet L. Uptake of plasmid/glycosylated polymer complexes and gene transfer efficiency in differentiated airway epithelial cells. J Gene Med 2003; 5: 38-48.

[44] Derrien D, Midoux P, Petit C. Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators. Glycoconj J 1989; 6: 241-255.

[45] Liang WW, Shi X, Deshpande D, Malanga CJ, Rojanasakul Y. Oligonucleotide targeting to alveolar macrophages by mannose receptormediated endocytosis. Biochim Biophys Acta 1996; 1279: 227-234.

[46] Harrison J, Shi X, Wang L, Ma JK, Rojanasakul Y. Novel delivery of antioxidant enzyme catalase to alveolar macrophages by Fc receptormediated endocytosis. Pharm Res 1994; 11: 1110-1114.

[47] Rojanasakul Y, Wang LY, Malanga CJ, Ma JK, Liaw J. Targeted gene delivery to alveolar macrophages via Fc receptor-mediated endocytosis. Pharm Res 1994; 11: 1731-1736.

[48] Briscoe P, Caniggia I, Graves A. Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am J Physiol 1995; 268: L374-L380.

[49] Ross GF, Morris RE, Ciraolo G. Surfactant protein A-polylysine conjugates for delivery of DNA to airway cells in culture. Human Gene Ther 1995; 6: 31-40.

[50] Walther FJ, David-Cu R, Supnet MC, Longo ML, Fan BR, Bruni R. Uptake of antioxidants in surfactant liposomes by cultured alveolar type II cells is enhanced by SP-A. Am J Physiol 1993; 265: L330-L339.

[51] Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS. Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther 2000; 7: 262-268.

[52] Cristiano RJ, Roth JA. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 1996; 3: 4-10.

[53] Yanagihara K, Cheng H, Cheng PW. Effects of epidermal growth factor, transferrin, and insulin on lipofection efficiency in human lung carcinoma cells. Cancer Gene Ther 2000; 7: 59-65.

[54] Gladysheva IP, Moroz NA, Karmakova TA, Nemtsova ER, Yakubovskaya RI, Larionova NI. Immunoconjugates of soybean Bowman-Birk protease inhibitor as targeted antitumor polymeric agents. J Drug Target 2001; 9: 303-316.

[55] Mastrobattista E, Storm G, Van Bloois L. Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim Biophys Acta 1999; 1419: 353-363.

[56] Jost PJ, Harbottle RP, Knight A, Miller AD, Coutelle C, Schneider H. A novel peptide, THALWHT, for the targeting of human airway epithelia. FEBS Lett 2001; 489: 263-269.

[57] Schneider H, Harbottle RP, Yokosaki Y, Jost P, Coutelle C. Targeted gene delivery into alpha9beta1-integrin-displaying cells by a synthetic peptide. FEBS Lett 1999; 458: 329-332.

[58] Scott ES, Wiseman JW, Evans MJ, Colledge WH. Enhanced gene delivery to human airway epithelial cells using an integrin-targeting lipoplex. J Gene Med 2001; 3: 125-134.

[59] Kreda SM, Pickles RJ, Lazarowski ER, Boucher RC. G-protein coupled receptors as targets for gene transfer vectors using natural small molecule ligands. Nat Biotechnol 2000; 18: 635-640.

[60] Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 1998; 15: 587-627.

[61] Deshpande D, Toledo-Velasquez D, Wang LY, Malanga CJ, Ma JK, Rojanasakul Y. Receptor-mediated peptide delivery in pulmonary epithelial monolayers. Pharm Res 1994; 11: 1121-1126.

[62] Franks TJ, Colby TV, Travis WD, Tuder RM, Reynolds HY, Brody AR, Cardoso WV, Crystal RG, Drake CJ, Engelhardt J. Resident cellular components of the human lung: current knowledge and goals for research on cell phenotyping and function. Proc Am Thorac Soc 2008; 5: 763–766.

[63] Giordano RJ, Edwards JK, Tuder RM, Arap W, Pasqualini R. Combinatorial ligand-directed lung targeting. Proc Am Thoracic Soc 2009; 6: 411-415.

[64] Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007; 28: 869-876.

[65] Reddy LH, Murthy RSR. Etoposide loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release and stability evaluation. AAPS PharmSciTech 2005; 6(2): E158-E166

[66] Lepoittevin B, Masson S, Huc V, Haut C, Roger P. Synthesis and characterization of glycosylated nanoparticles. E-polymers 2006; 32: 1-15.

Int. J. Med. Phar. Drug Re., 7(4), 2023

Online Available at: https://www.aipublications.com/ijmpd/

71

[67] Lee SH, Zhang Z, Feng S-S. Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials 2007; 28: 2041-2050.

[68] Gao F-P, Zhang H-Z, Liu L-R, Wang Y-S, Jiang Q, Zhang Q-Q. Preparation and physicochemical characteristics of deoxycholic modified carboxymethyl curdlan conjugates. Carbohyrate Polymers 2008; 71(4): 606-613.

[69] Paranjape PV, Chen Y, Kholodovych V, Welsh D, Stein S, Sinko PJ. Tumor-targeted bioconjugate based delivery of Camptothecin: design, synthesis and in vitro evaluation. J Control Release 2004; 100(2): 275-292.

[70] Jain A, Agrawal A, Majumder S, Lariya N, Khaya A, Agrawal H, Majumdar S, Agrawal GP. Mannosylated solid-lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 2010; 148(3): 359-367.

[71] Chandna P, Saad M, Wang Y, Wer E, Khandare J, Vetcher AA, Soldatenkov VA, Minko T. Targeted proapoptotic anticancer drug delivery system. Mol Pharm 2007; 4(5): 668–678.

[72] Park EK, Lee SB, Lee YM. Preparation and characterization of methoxy poly(ethylene glycol)/poly (ε-caprolactone) amphiphilic block coplymeric nanospheres for tumor-specific folate mediated targeting of anticancer drugs. Biomaterials 2005; 26: 1053-1061.

[73] Park K, Lee GY, Kim Y-S, Yu M, Park R-W, Kim I-S, Kim SY, Byun Y. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release 2006; 114: 300–306.

[74] Bozkir A, Saka AM. Formulation and evaluation of 5-FU nanoparticles with factorialdesign based studies. Farmaco 2005; 60(10): 840-846.

[75] Maghsoudi A, Shojaosadati SA, Vasheghani-Farahani E. 5-fluorouracil loaded BSA nanoparticles: Formulation optimization and in vitro release study. AAPS PharmaSciTech 2008; 9(4): 1092-1096.

[76] Zhang D-Y, Shen X-Z, Wanf J-Y, Dong L, Zheng Y-L, Wu L-L. Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice. World J Gastroenterol 2008; 14(22): 3554-3562.

[77] Yassin AEB, Anwer MD, Mowafy HA, El-Bagory IM, Bayomi MA, Alsarra IA. Optimization of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci 2010; 7(6): 398-408.

[78] Tosi G, Bortot B, Ruozi B, Dolcetta D, Vandelli MA, Forni F, Severini GM. Potential use of polymeric nanoparticles for drug delivery across the blood brain barrier. Curr Med Chem 2013; 20(17): 22112-22125.

[79] Cho JK, Park BD, Lee YS. A novel core-shell type polymer support for solid-phase peptide synthesis. Tet Lett 2000; 41: 7481-7485

[80] Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neurovasculature. Biomaterials 2010; 31 (8): 2278-2292

[81] Dubey N, Varshney R, Shukla J, Ganeshpurkar A, Hazari PP, Bandopadhyay GP, Mishra AK, Trivedi P. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog. Drug Del 2012; 19: 132-142

[82] Danhier F, Lecouturier N, Vroman B, Jerome C, Marchand-Brynaert J, Feron O, Preat V. Paclitaxel loaded PEGylated PLGA based nanoparticles: In vitro and in vivo evaluation. J Control Release 2009; 133: 11-17

[83] Kuo G, Gao J, Wang H, Chen H, Li B, Zhang D et al. Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J Biochem Mol Bio 2007; 40 (5): 731-739

Int. J. Med. Phar. Drug Re., 7(4), 2023

Online Available at: https://www.aipublications.com/ijmpd/

72